DOI: https://doi.org/10.22141/2224-0551.13.8.2018.154159

Influence of the intestinal microbiota on the formation and development of non-alcoholic fatty liver disease in children

L.K. Parkhomenko, L.A. Strashok, M.A. Khomenko

Abstract


Recently, non-alcoholic fatty liver disease has become one of the most common liver diseases among adults and is increasingly diagnosed in children and adolescents. This leads to a significant interest in finding new links in the etiopathogenesis of the disease. With the development and application of modern methods for studying the intestinal microbiota, significant progress has been made in understanding its impact on human health. The review presents current data that demonstrate the role of the intestinal microbiota in the formation and deve­lopment of non-alcoholic fatty liver disease in children.

Keywords


intestinal microbiota; non-alcoholic fatty liver di­sease; adolescents; review

References


Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol. 2017;10(11):1225-1237. doi: 10.1080/17512433.2017.1365599.

Ranucci G, Spagnuolo MI, Iorio R. Obese children with fatty liver: Between reality and disease mongering. World J Gastroenterol. 2017;23(47):8277-8282. doi: 10.3748/wjg.v23.i47.8277.

Stepanov YuM, Abaturov AYe, Zavgorodnia NYu, Skyrda. IYu. Non-alcoholic fatty liver disease in children: Current View on Diagnostics and Treatment (Part I). Gastroenterologia. 2015;(56):99-107. (in Ukrainian).

De Alwis NM, Anstee QM, Day CP. How to diagnose nonalcoholic fatty liver disease. Dig Dis. 2016;34 Suppl 1:19-26. doi: 10.1159/000447277.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.

Bush H, Golabi P, Younossi ZM. Pediatric non-alcoholic fatty liver disease. Children (Basel). 2017; 4(6). pii: E48. doi: 10.3390/children4060048.

Xu S, Xue Y. Pediatric obesity: Causes, symptoms, prevention and treatment. Exp Ther Med. 2016;11(1):15-20. doi:10.3892/etm.2015.2853.

Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. doi: 10.1038/nrgastro.2017.109.

Betancourt-Garcia MM, Arguelles A, Montes J, Hernandez A, Singh M, Forse RA. Pediatric nonalcoholic fatty liver disease: the rise of a lethal disease among mexican american hispanic children. Obes Surg. 2017;27(1):236-244. doi: 10.1007/s11695-016-2440-5.

Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0140908. doi: 10.1371/journal.pone.0140908.

Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: 10.1002/hep.29367.

Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-55. doi: 10.1053/j.gastro.2014.11.039.

Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58(11):1538-44. doi: 10.1136/gut.2008.171280.

Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". World J Gastroenterol. 2018;24(27):2974-2983. doi: 10.3748/wjg.v24.i27.2974.

Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Int J Mol Sci. 2016;17(6). pii: E947. doi: 10.3390/ijms17060947.

Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7(6):471-9. doi: 10.1111/j.2047-6310.2012.00082.x.

Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients. 2017;9(4):387. pii: E387. doi: 10.3390/nu9040387.

Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–1560. doi: 10.3390/nu5051544.

Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016;22(36):8078-93. doi: 10.3748/wjg.v22.i36.8078.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48. doi: 10.1016/j.metabol.2015.12.012.

Miele L, Marrone G, Lauritano С, et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des. 2013;19(29):5314-24.

Zhang X, Ji X, Wang Q, Zhong Li J. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell. 2018;9(2):164-177. doi: 10.1007/s13238-017-0436-0.

Del Chierico F, Nobili V, Vernocchi P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65(2):451-464. doi: 10.1002/hep.28572.

Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412-25. doi: 10.1038/nrgastro.2016.85.

Cotillard A, Kennedy SP, Kong LC et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500(7464):585-8. doi: 10.1038/nature12480.

Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-9. doi: 10.1002/hep.26093.

Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49(8):385-399. doi: 10.1152/physiolgenomics.00012.2017.

Bervoets L, Van Hoorenbeeck K, Kortleven I, et al. Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog. 2013;5(1):10. doi: 10.1186/1757-4749-5-10.

Koliada A, Syzenko G, Moseiko V, et al. Association between body mass index and Firmicutes/Bacteroidetes ratio in an adult Ukrainian population. BMC Microbiol. 2017;17(1):120. doi: 10.1186/s12866-017-1027-1.

Zavgorodnia NYu, Zygalo EV, Lukianenko OYu, Babii SA. Role of the Gut Microbiota in the Development of Lipid and Carbohydrate Metabolism in the Liver Steatosis in Children. Zdorovʹe rebenka. 2016;(76):41-44. doi: 10.22141/2224-0551.8.76.2016.90822. (in Ukrainian).

Li W, Zhang K, Yang H. Pectin alleviates high fat (lard) diet-induced nonalcoholic fatty liver disease in mice: possible role of short-chain fatty acids and gut microbiota regulated by pectin. J Agric Food Chem. 2018;66(30):8015-8025. doi: 10.1021/acs.jafc.8b02979.

Den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. doi: 10.1194/jlr.R036012.

Murugesan S, Nirmalkar K, Hoyo-Vadillo C, García-Espitia M, Ramírez-Sánchez D, García-Mena J. Gut microbiome production of short-chain fatty acids and obesity in children. Eur J Clin Microbiol Infect Dis. 2018;37(4):621-625. doi: 10.1007/s10096-017-3143-0.

Kaji I, Karaki S, Kuwahara A. Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion. 2014;89(1):31-6. doi: 10.1159/000356211.

Payne AN, Chassard C, Zimmermann M, Müller P, Stinca S, Lacroix C. The metabolic activity of gut microbiota in obese children is increased compared with normal-weight children and exhibits more exhaustive substrate utilization. Nutr Diabetes. 2011;1(7):e12. doi:10.1038/nutd.2011.8.

Goffredo M, Mass K, Parks EJ, et al. Role of gut microbiota and short chain fatty acids in modulating energy harvest and fat partitioning in youth. J Clin Endocrinol Metab. 2016;101(11):4367-4376. doi: 10.1210/jc.2016-1797.

Murugesan S, Ulloa-Martínez M, Martínez-Rojano H, et al. Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children. Eur J Clin Microbiol Infect Dis. 2015;34(7):1337-46. doi: 10.1007/s10096-015-2355-4.

Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6(12):5583-99. doi: 10.3390/nu6125583.

Fithriania, Suryadarma P, Mangunwidjaja D. Metabolic engineering of escherichia coli cells for ethanol production under aerobic conditions. Procedia Chemistry. 2015;16:600-607. doi: 10.1016/j.proche.2015.12.098.

Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1-9. doi: 10.1093/femsec/fiu002.

Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One. 2010;5(3):e9570. doi: 10.1371/journal.pone.0009570.

Brenner DA, Paik YH, Schnabl B. Role of gut microbiota in liver disease. J Clin Gastroenterol. 2015;49 Suppl 1:S25-7. doi: 10.1097/MCG.0000000000000391.

Çakır M, Aksel İşbilen A, Eyüpoğlu İ, et al. Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease. Turk J Gastroenterol. 2017;28(5):377-383. doi: 10.5152/tjg.2017.17084.

Engstler AJ, Aumiller T, Degen C, et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2016;65(9):1564-71. doi: 10.1136/gutjnl-2014-308379.

Wahlström A, Kovatcheva-Datchary P, Stahlman M, Bäckhed F, Marschall HU. Crosstalk between bile acids and gut microbiota and its impact on Farnesoid X Receptor signalling. Dig Dis. 2017;35(3):246-250. doi: 10.1159/000450982.

Nobili V, Alisi A, Mosca A, et al. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Liver Int. 2018;38(2):342-349. doi: 10.1111/liv.13531.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4.

Poeta M, Pierri L, Vajro P. Gut-liver axis derangement in non-alcoholic fatty liver disease. Children (Basel). 2017 Aug 2;4(8). pii: E66. doi: 10.3390/children4080066.

Sturgeon С, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers. 2016;4(4):e1251384. doi: 10.1080/21688370.2016.1251384.

Ohlsson B, Orho-Melander M, Nilsson PM. Higher levels of serum zonulin may rather be associated with increased risk of obesity and hyperlipidemia, than with gastrointestinal symptoms or disease manifestations. Int J Mol Sci. 2017 Mar 8;18(3). pii: E582. doi: 10.3390/ijms18030582.

Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877-87. doi: 10.1002/hep.22848.

Pacifico L, Bonci E, Marandola L, Romaggioli S, Bascetta S, Chiesa C. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(45):17107-14. doi: 10.3748/wjg.v20.i45.17107.

Belei O, Olariu L, Dobrescu A, Marcovici T, Marginean O. The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. J Pediatr Endocrinol Metab. 2017;30(11):1161-1168. doi: 10.1515/jpem-2017-0252.

Nier A, Engstler AJ, Maier IB, Bergheim I. Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. PLoS One. 2017;12(9):e0183282. doi: 10.1371/journal.pone.0183282.

Guercio Nuzio S, Di Stasi M, Pierri L et al. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr Obes. 2017;12(6):446-452. doi: 10.1111/ijpo.12164.

Yuan J, Baker SS, Liu W, et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2014;29(6):1292-8. doi: 10.1111/jgh.12510.




Copyright (c) 2019 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта